Delcath Announces Commercial Licensing Agreement for CHEMOSAT®
26. Dezember 2018 08:00 ET
|
Delcath Systems, Inc.
7 Year Agreement with medac to Maximize Potential of CHEMOSAT in Europe Upfront and Milestone Payments Provide Additional Resources to Advance Clinical Development in the U.S. NEW YORK, Dec. 26,...
Delcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification
18. Dezember 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces Third Quarter Fiscal 2018 Financial Results
13. November 2018 16:52 ET
|
Delcath Systems, Inc.
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces...
Delcath Announces Enrollment of First Patient in ALIGN Trial
18. Oktober 2018 08:00 ET
|
Delcath Systems, Inc.
The University of Tennessee Health Science Center, Methodist University Hospital, and West Cancer Center Begin Treatments in New Registration Trial for Intrahepatic Cholangiocarcinoma NEW YORK, Oct. ...
CORRECTING and REPLACING – Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
15. Oktober 2018 10:57 ET
|
Delcath Systems, Inc.
Seven Cancer Centers in United States Open for Enrollment in Amended Trial NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Delcath...
Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
15. Oktober 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology
04. Oktober 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Raises $8.1 Million from Shareholders in Rights Offering
27. September 2018 16:05 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announces...
Data from Prospective Phase 2 Study Investigating Delcath’s PHP Therapy presented at CIRSE 2018
26. September 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Data on Delcath’s PHP Therapy presented at CIRSE 2018
24. September 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...